Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling
Open Access
- 6 November 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (5) , 5521-5537
Abstract
Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/mTOR signalingKeywords
This publication has 93 references indexed in Scilit:
- Cancer cell metabolism: implications for therapeutic targetsExperimental & Molecular Medicine, 2013
- Targeting cellular metabolism to improve cancer therapeuticsCell Death & Disease, 2013
- Targeting PI3K in Cancer: Any Good News?Frontiers in Oncology, 2013
- Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-Bromopyruvate Propyl EsterJournal of Bioenergetics and Biomembranes, 2012
- Systems biology of the metabolic network regulated by the Akt pathwayBiotechnology Advances, 2012
- Hypoxia-Inducible Factors and the Response to Hypoxic StressMolecular Cell, 2010
- PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell linesCancer Letters, 2009
- Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphomaLeukemia, 2009
- Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesisSeminars in Cancer Biology, 2009
- Cancer Cell Metabolism: Warburg and BeyondCell, 2008